The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Touk the delivery mechanism works, there’s no doubt about that. The complexity is navigating the pharmacokinetic landscape and understanding how and when this treatment is applicable ie. does the tumour exhibit sufficient active fap and can ava6000 be delivered to the tumour site in sufficient concentrations.
I'm fairly confident this will rise up at some point in the not too distant future. It's perfectly normal for investors to feel aggrieved in these circumstances and for it to seem like the sun will never come back up.
As for baying for AS's blood, my take is that he should remain and continue to build the team around him that has the commercial and clinical experience needed to get this over the finish line, which I happen to think is a process that is already underway.
it's also yet another example of "the market" being represented by a couple of thick as pig **** participants, when it comes to understanding the voracity of the underlying tech. do you hear that wyndrum, i don't want hear it from you again that the sp reflects where the trial or the tech is. two prime examples, so **** right off.
interviewing another bit of vermin. this time ph rambles on at the guy for about 5 minutes extolling the virtues of avacta and their wonderful teck and lamenting at how difficult it is to raise money at this time. guy just replies:
"yeah, no idea what you're talking about mate. but yeah of course companies have to raise money before they need it or the investors will take advantage and offer less and you'll need to accept it, huh huh. then you've got shorters, like me, who come in shorting the stock looking to cover in the placing"
yeah, you ****, you can do that because you've been tipped off that there's a placing coming in at x. there he is, that's what he looks like if you want to throw your tomatoes at him.
Indeed, and a quick search of paclitaxel, the example given by CC, shows that the dosing regimen changes depending on the condition, and in future I imagine AVA6000 will also be the same. That said, there are a million different dosing regimens that could be explored, so that is something that clinicians may experiment in future trials, and not necessarily something that would be adopted now. But who knows, the trial is evolving before our eyes!
Lot's of tangential thought processes going on, but it was actually stated in the RNS, that there would be further updates to be given at AACR:
"We are now in a very strong position to deliver significant clinical and commercial milestones relating to AVA6000 and the wider pre|CISION? platform, and we are looking forward to providing a further detailed update on the clinical trial at the American Association for Cancer Research meeting in April."
Since the drop to the 50's, 76m shares have been soaked up at this price, on top of the placing number. That's a pretty decent support structure, and don't see how/why it could push below 50 without it getting snapped up.
This whole business of could or couldn't they have raised 25m from PI's, I have little doubt it would have been considered, and advise sought on whether they could have pulled it off. Would the city boys have been tipped off and ruined the party? The result may have been a crashed share price and a failed PI raise. Just don't know. At the end of it all, the dilution is just 20%, not 50%, as it appears from the share price, and the cash gives avacta enough runway to reach some serious value events.
That's part of the excitement of this trial. By targeting high fap expressing tumours the net is cast very wide indeed, but that requires vast resources to cover, and for each indication there will be tuning to be done. The safety profile to date also allows for a wide range of experimental dosing regimens which would ordinarily be limited by toxicity. The two combined means the market could be very large indeed, but requires time and resources to match.
Oh for sure that is the case. That is the pharmacokinetics aspect of all of this. Some tumours won't express high fap, others are in low blood zones, such as bone cancers. Part of the challenge of oncologists has always been finding the right treatment for a tumour.